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Abstract
Single nucleotide polymorphisms (SNP) in the TLR5 gene have been associated with human inflammatory bowel disease
(IBD) and animal models of this disease. We recently demonstrated a significant association between three non-
synonymous SNPs in the canine TLR5 gene and IBD in German shepherd dogs (GSDs). However, so far, no direct link
between these SNPs and a disturbance in TLR5 function was shown. In the present study, we determined the functional
significance of the canine TLR5 SNPs by transfecting the identified risk-protective and risk-associated haplotype into human
embryonic kidney cells (HEK) and assessed nuclear factor-kappa B (NF-kB) activation and CXCL8 production after
stimulation. In addition, a whole blood assay for TLR5 activation was developed using blood derived from carrier dogs of
either haplotype. There was a significant increase in NF-kB activity when cells transfected with the risk-associated TLR5
haplotype were stimulated with flagellin compared to the cells expressing the risk-protective TLR5 haplotype. This
difference in NFkB activation correlated with CXCL8 expression in the supernatant measured by ELISA. Furthermore, whole
blood taken from carrier dogs of the risk-associated TLR5 haplotype produced significantly more TNF after stimulation with
flagellin compared to that taken from carriers of the risk-protective haplotype. Thus, we show for the first time a direct
functional impact of the canine IBD risk-associated TLR5 haplotype, which results in hyper-responsiveness to flagellin
compared to the IBD risk-protective TLR5 haplotype. Our data potentially suggest that similarly to human IBD and
experimental models, TLR5 may also play a role in canine IBD. Blocking the hyper-responsive receptor found in susceptible
dogs with IBD may alleviate the inappropriate inflammation seen in this disease.
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Introduction
The healthy gut is able to regulate inflammatory responses to
commensal bacteria and food antigens whilst maintaining the
capacity to respond to pathogens [1][2][3]. This distinction relies
in part on appropriately functioning pattern recognition receptors
(PRRs) such as Toll-like receptors (TLRs); which are ideally
situated in intestinal epithelial cells and recognise microbe
associated molecular patterns (MAMPs) [4]. In humans, the
breakdown in this immunological tolerance to commensal and
dietary antigens is thought to play an important role in the
pathogenesis of inflammatory bowel disease (IBD) [2] and the
same may also be true in dogs.
IBD is a chronic debilitating disease and occurs in both, humans
and dogs. In dogs, it represents a group of disorders characterised by
chronic gastrointestinal signs, with histological evidence of inflam-
mation in the lamina propria of the small intestine, large intestine or
both [5]. In humans, IBD consists of Crohn’s disease (CD) and
ulcerative colitis (UC) [6]. The histopathological changes seen in
human IBD are different to the ones in canine IBD, in that extensive
granulomasarethepathognomonicfeaturesofCD[7].Althoughthe
exact aetiology of IBD in both species is unknown, it is considered a
multi-factorial disease with the mucosal immune system, microbiota,
genetics and environment all playing a role [8][7][6][9]. Given the
similarity of clinical signs, it is likely that canine and human IBD
share similar aetiological factors as studies have already highlighted
the importance of TLRs in IBD in both species. In human IBD,
TLR 2, 4 and 6 have been shown to be upregulated in the intestinal
mucosa of affected patients [10][11][12], whilst some studies have
documented a down-regulation of TLR5 in the mucosa of mouse
models and patients with UC [13][14]. Similarly, we have recently
shown an upregulation of TLR4 and a down-regulation of TLR5 at
the mRNA level specifically in German shepherd dogs (GSDs) with
IBD [15].
Moreover, we recently identified three non-synonymous single
nucleotide polymorphisms (SNPs) present in the TLR5 exon
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IBD in GSDs [16]. One of these, G22A was found to be positively
associated with IBD whereas the other two SNPs, C100T and
T1844C were found to be significantly protective. GSDs carrying
the TLR5 risk-associated haplotype (ACC) were five times more
likely to develop IBD [16]. Furthermore, two of the non-
synonymous TLR5 SNPs (C100T and T1844C) were also
significantly protective for the development of IBD in 38 other
canine breeds [17].
Genetic studies conducted in human IBD have shown that a
polymorphism in the TLR5 gene (C1174T) results in a truncated
form of TLR5 that is significantly protective for CD [18].
Therefore, as polymorphisms in TLR5 are associated with disease
phenotypes in dogs and humans, this suggests that certain
polymorphisms have functional consequences. Indeed, functional
studies in both humans with IBD and animal models have
confirmed that TLR5 plays a significant role in the aberrant
inflammation seen in this disease [19]. The human truncated
TLR5 has been shown to abrogate flagellin induced signalling
[19]. Thus, a non-functional TLR5 receptor may be protective for
CD. Moreover, studies in a murine model of IBD suggest that
TLR5 signalling could play a protective role in IBD as TLR5
knockout mice develop spontaneous colitis [20].
As the canine genome exhibits vast linkage disequilibrium [21],
it is possible that the SNPs found in the TLR5 gene that are
significantly associated with canine IBD may be in linkage with
another, possibly causative gene. Hence to confirm a primary role
of TLR5 in canine IBD, functional studies would be needed.
Therefore the aim of this study was to determine the potential
functional significance of the canine TLR5 SNPs on the
pathogenesis of IBD in vitro and ex vivo. Our results suggest that
a hyper-responsive TLR5 receptor may play a role in the
inappropriate inflammation seen in some cases of canine IBD.
Results
Confirmation of successful production of canine
risk-protective (RP) and risk-associated (RA) TLR5-YFP
by HEK 293 cells
In order to compare the functional response of the indentified
polymorphisms, the TLR5 sequence of the IBD risk-protective
haplotype (G22A haplotype GTT) and the IBD risk-associated
haplotype (G22A haplotype ACC) [16] were cloned in to
pcDNA3.1 plasmids containing YFP to monitor successful expres-
sion.Toenhancethe uniformityofthetransformedpopulation,cells
stably expressing either form of TLR5-YFP were subsequently
analysed and sorted for high expressing cells, resulting in a similar
percentage of cells expressing the respective molecule.
Confocal microscopy
As flow cytometric analysis does not allow for complete
discrimination of surface versus intracellular expression of cani-
neTLR5-YFP, cells were analysed additionally by confocal
microscopy. In agreement with the FACS data, YFP expression
was detected in a similar percentage of HEK 293 cells transfected
with both caTLR5 variants. YFP expression concentrated in a ring-
likeshape at the periphery of the cell as well as dispersed throughout
the cytoplasm, suggesting presence of both canineTLR5RP-YFP
and canineTLR5RA-YFP predominantly at the cell surface. No
YFP signal was seen in control HEK 293 cells (Figure 1).
Having established expression of both caTLR5 constructs, we
next assessed their functionality in response to different TLR
ligands. To do so, HEK293 cells transfected with either human
TLR5, canine TLR5RP or canine TLR5RA were stimulated with
recombinant FliC (rFliC), LPS or PAM3CSK4, and the results
compared to unstimulated cells. Whereas absolute values were in
general higher in HEK293 cells transfected with human TLR5
(Figure 2), all responses showed a very similar response pattern
when data were expressed relative to the medium-control
(Figure 2). Interestingly, stimulation of RA-caTLR5 compared to
RP-caTLR5 resulted in a significantly increased NF-kB activation
when cells were stimulated with the higher concentration of rFliC
(0.1 ug/ml) (p,0.05), but not with the lower dose (0.01 ug/ml)
(p=0.47) (Figure 2). In contrast, none of the other TLR-ligands
tested resulted in an increase in NF-kB activation (Figure 2).
CXCL8 production is increased after stimulation of
RA-caTLR5
As stimulation of RA-caTLR5 did lead to an increased NFkB
activation, we next tested whether this was associated with an
increase in protein production. Thus, CXCL8 production in
supernatants taken from one of the above experiments was
analysed by ELISA. Data are presented as either total CXCL8
concentration (Figure 3), or as fold-increase determined relative to
unstimulated cells (Figure 3). Similar to the changes seen with
regards to NF-kB activation, CXCL8 production was significantly
increased in HEK293 cells transfected with RA-caTLR5 com-
pared to RP-caTLR5 when using the higher rFliC concentration
(0.1 ug/ml) (p,0.05), but not with the lower rFliC concentration
(0.01 mg/ml) (p=0.47).
Carriers of the RA-TLR5 haplotype show increased TNF
production in response to flagellin
To assess whether the differences seen between the two TLR5
genotypes can be verified by means of an ex-vivo approach, a whole
blood assay was developed. Having established the functionality of
the whole blood assay with regards to different PRR ligands and
concentrations in control dogs (Figure 4), GSDs for which TLR5
genotype information was available were recruited onto the study.
Residual blood from the collection of haematology and serum
biochemistry profiles was used in the whole blood assay as
described in materials and methods.
A total number of 23 GSDs carrying the RP haplotype and 5
GSDs carrying the RA haplotype were recruited (table 1 and 2).
Comparing 5 GSDs each carrying the RP TLR5 haplotype but
with different phenotype (IBD vs healthy), no significant
differences in TNF production were seen in response to the
stimulation, independent of disease status. Increasing amounts of
rFliC led to a reduced production of TNF (Figure 5). In contrast,
there was a tendency to an increased production of TNF in
response to increasing amounts of LPS (Figure 5), and hardly any
differences were seen when using the different S. dublin dilutions
(stock concentration: 15.64610
8 CFU/ml).
Comparing the results obtained for GSD with the RP (n=23) or
RA (n=5) TLR5 haplotype independent of disease status showed
that GSDs carrying the RA TLR5 produced significantly more
TNF-a in the supernatant compared to GSDs carrying the RP
TLR5 after stimulation with flagellin (median TNF-a production
in RP dogs: 3.3 pg/ml, range 0–27.4; median TNF-a production
in RA dogs: 16.7 pg/ml, range 8.9–47.7; Mann Whitney U
p=0.006) (figure 6).
Expression of TLR4 and TLR5 has been reported for human
peripheral blood T lymphocytes, monocytes, neutrophils and
eosinophils [22][23][24][25][26]. Although, in dogs it has been
shown that blood-derived monocytes express TLR4 and TLR5
and stimulation with LPS and flagellin results in TNFa production
[27], data on TLR expression on eosinophils, neutrophils and
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that any significant differences seen in TNFa production were not
due to significant differences between the concentrations of
leucocyte subsets, statistical analysis was carried out on the
haematology results obtained from each dog. There were no
significant differences in the numbers of neutrophils, monocytes or
eosinophils between the group of healthy GSD and the group of
GSD with IBD (p.0.05; data not shown). However, there was a
borderline significantly greater concentration of lymphocytes in
the healthy GSD group compared to the IBD group (p=0.05). In
addition, there were no significant differences in the concentra-
tions of neutrophils, lymphocytes, monocytes or eosinophils
between the IBD GSD group with RP TLR5 haplotype and the
IBD GSD group with RA TLR5 polymorphisms (p.0.05; data
not shown). All parameters for the serum biochemistry profile were
within the reference range for all dogs.
Discussion
As initial association studies suggested a significant effect of
canine TLR5 SNPs with the occurrence of IBD in GSDs [16], we
investigated whether these SNPs resulted in functional differences
of the expressed protein constructs. The results of the in vitro
analysis using both TLR5 haplotypes expressed in HEK cells
described in the present study clearly demonstrate that the TLR5
risk-associated haplotype (ACC) is significantly hyper-responsive
to flagellin compared to the TLR5 risk-protective haplotype
(GTT). In addition, we were able to show that this hyper-
responsiveness also exists when whole blood is stimulated with the
appropriate ligands. The observed hyper-responsiveness to
flagellin could in part be responsible for the inappropriate
inflammation seen in dogs with IBD carrying this haplotype of
the TLR5 gene.
The importance of defective TLR5 haplotypes for the
pathogenesis of IBD has been demonstrated before in human
patients and animal models [18,20]. In human subjects, a stop
codon in TLR5 which abrogates flagellin signalling is associated
with protection against CD in a Jewish cohort [18], suggesting that
abolishing flagellin signalling may help prevent IBD. In addition,
subjects with this TLR5 genotype produced significantly lower
concentrations of pro-inflammatory cytokines in intestinal lesions
compared to individuals carrying the wild-type genotype [19].
Figure 1. Confocal microscopic analysis of canineTLR5RP-YFP and canineTLR5RA-YFP. Transfected HEK 293 cells were cultured as
described and analysed for fluorescence. Row A: Overlay of fluorescence of YFP conjugated to canineTLR5RP (yellow) and Hoechst stained nuclear
fluorescence (blue); Row B: Overlay of fluorescence of YFP conjugated to canineTLR5RA (yellow) and Hoechst stained nuclear fluorescence (blue);
Row C: Hoechst stained untransfected HEK 293 cell nuclear fluorescence (blue). Bar, 50 mm.
doi:10.1371/journal.pone.0030117.g001
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association between specific TLR5 haplotypes and the develop-
ment of IBD in GSDs as well as in 38 other canine breeds
[17][16].
The data of the present study suggest that dogs carrying the risk-
associated TLR5 haplotype are hyper-responsive to flagellin.
Thus, it could be speculated that this hyper-responsiveness plays a
significant role in the pathogenesis of canine IBD. Therefore,
blocking the excess response to flagellin in susceptible dogs could
potentially help abolish the inappropriate inflammation seen in
canine IBD. However, under physiological conditions, TLR5 may
indeed exert a beneficial effect in the gut. Sensing of flagellin/
flagellated bacteria by TLR5 expressed in the intestinal epithelia
has been shown to enhance the expression of bacteriocidal and
barrier-enhancing mediators [28][29][30][31], to reduce epithelial
cell apoptosis, to limit disease severity during enteric infection
[31], and to contribute to epithelial repair [31]. This suggests that
epithelia are able to re-establish homeostasis in an autonomous
Figure 2. Activation of NF-kB in stimulated HEK 293 cells stably transfected with human TLR5, canineTLR5RP-YFP or
canineTLR5RA-YFP. Transfected human TLR5, canineTLR5RP-YFP and canineTLR5RA-YFP HEK 293 cells were incubated with flagellin, PAM3CSK4,
LPS or media for 24 hours before production of NF-kB was analysed by a luciferase reporter gene assay. The results displayed are the mean values of
four independent experiments each with three repeats under the same conditions, with error bars illustrating standard error of the mean. Data are
presented either as relative luciferase units (RLU) (A) or converted into fold-increase by comparing with RLU values obtained for unstimulated cells
with media (B). There was a significant increase in the baseline and fold-increase in RLU values in canineTLR5RA-YFP compared to canineTLR5RP-YFP
when the cells were stimulated with 0.1 mg/ml of flagellin (p=0.034).
doi:10.1371/journal.pone.0030117.g002
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[31]. Therefore TLR5 also plays a beneficial role in the gut and
blocking such signalling entirely may impair important defence
mechanisms. Indeed, it has been shown that TLR5 knockout mice
have more severe gut pathology and develop spontaneous colitis
[20].
However, the presence of the RA haplotype alone may not
entirely explain the differences seen in clinical signs. Interestingly,
a recent report suggests that whilst epithelial NF-kB activation
may be protective, immune cell-derived NF-kB activation drives
colitis [32]. Furthermore, TLR5 ligation by flagellin converted
tolerogenic DCs into activating APC, producing IL12 but not
IL10, and promoting differentiation of naı ¨ve T cells into TH1 cells
[33]. Similarly, murine DCs present in the intestinal lamina
propria display high levels of TLR5-mediated production of IL12,
but not IL10 when stimulated with flagellin [34]. Thus, epithelial
TLR5 activation may exert a protective role in the gut, whereas
breach of this barrier during inflammatory conditions such as seen
in IBD could lead to an exaggerated response to flagellin, similar
as seen in dextran-sodium sulphate induced colitis in mice [35]. It
Figure 3. Activation of CXCL8 secretion in stimulated HEK 293 cells stably transfected with human TLR5, canineTLR5RP-YFP or
canineTLR5RA-YFP. Transfected human TLR5, canineTLR5RP-YFP and canineTLR5RA-YFP HEK 293 cells were incubated with flagellin or media for
24 hours before production of CXCL8 was analysed by an ELISA. The results displayed are the mean values of one experiment with three repeats
under the same conditions, with error bars illustrating standard error of the mean. Data are presented either as concentration (pg/ml) (A) or
converted into fold-increase by comparing to the concentration obtained for unstimulated cells with media (B). The CXCL8 production was
significantly higher in canineTLR5RA-YFP cells than in canineTLR5RP-YFP cells when stimulated with the higher flagellin concentration (0.1 mg/ml)
(p=0.025, one-tailed).
doi:10.1371/journal.pone.0030117.g003
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PLoS ONE | www.plosone.org 5 January 2012 | Volume 7 | Issue 1 | e30117Figure 4. Activation of TNFa secretion in whole blood stimulation assays with flagellin, LPS or Salmonella dublin. Whole blood was
diluted with twice the volume of RPMI and stimulated with flagellin, LPS or heat-inactivated Salmonella dublin at different concentrations for 24 hours
before production of TNFa was analysed by an ELISA. The results displayed are the mean values obtained from four healthy blood donor dogs (2
Labradors, 1 Greyhound and 1 Great Dane) each with two repeats under the same conditions, with error bars illustrating standard error of the mean.
doi:10.1371/journal.pone.0030117.g004
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leaky intestinal barrier may allow increased contact between
flagellin and TLR5 on immune cells, therefore increasing mucosal
inflammation in dogs carrying the RA haplotype. In addition, this
could explain why those dogs carrying the TLR5 RP haplotype
produce significantly less CXCL8 and are therefore less susceptible
to the development of chronic intestinal inflammation such as in
IBD.
In conclusion, TNF production in response to flagellin
stimulation was significantly higher in the group of IBD dogs
carrying TLR5 RA polymorphisms compared to the IBD group
carrying RP TLR5. The data from the whole-blood assay therefore
support those obtained using TLR5-expressing HEK293 cells with
regards to NF-kB activity and CXCL8 production.
As the results of one study indicated that TLR5 activation
systemically and within the mucosal surface may be controlled by
different mechanisms [36], further studies should aim to confirm
that risk-associated polymorphisms in canine TLR5 result in
hyper-responsive signalling to flagellin within the intestinal
mucosa.
Table 1. Phenotype of German shepherd dogs carrying the risk-protective TLR5 haplotype which were recruited onto the whole
blood stimulation assay study.
TLR5 Haplotype Age at sampling Sex Diagnosis
Treatment of IBD at time of
sampling
GGTTTT 4years MN Healthy n/a
GGTTTT 5years FE Healthy n/a
GGTTTT 7years FE Healthy n/a
GGTTTT 7years ME Healthy n/a
GGTTTT 8 years MN Healthy n/a
GGTTTT 9 years FN Healthy n/a
GGTTTT 8 years MN Healthy n/a
GGTTTT 6 years MN UTI n/a
GGTTTT 10 years FE Hemangiosarcoma n/a
GGTTTT 7 years Hemangiosarcoma n/a
GGTTTT 6 years Skin mass n/a
GGTTTT 3 years Lameness n/a
GGTTTT 12 years Myelopathy n/a
GGTTTT 1 year Lameness n/a
GGTTTT 7 years GI foreign body n/a
GGTTTT 8 years Lymphoma n/a
GGTTTT 5 years Otitis n/a
GGTTTT 6 years IBD Diet
GGTTTT 5years ME IBD Diet
GGTTTT 4years FN IBD Diet
GGTTTT 6years ME IBD Diet
GGTTTT 4years FN IBD Diet
GGTTTT 4 years MN IBD Corticosteroids
GSDs=German shepherd dogs, m=male, f=female, n=neutered, e=entire, IBD=Inflammatory Bowel Disease, n/a=not applicable.
doi:10.1371/journal.pone.0030117.t001
Table 2. Phenotype of German shepherd dogs carrying the risk-associated TLR5 haplotype which were recruited onto the whole
blood stimulation assay study.
TLR5 haplotype Age at sampling Sex Diagnosis
Treatment of IBD at time of
sampling
GGAGCT 7 years FN IBD Diet
GGGGTT 6 years FE IBD Diet
AGAGCT 4 years FN IBD Diet
AACTCT 7 years FN IBD Diet
AGCTCT 3 years MN Lameness n/a
GSDs=German shepherd dogs, m=male, f=female, n=neutered, e=entire, IBD=Inflammatory Bowel Disease, n/a=not applicable.
doi:10.1371/journal.pone.0030117.t002
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PLoS ONE | www.plosone.org 7 January 2012 | Volume 7 | Issue 1 | e30117Figure 5. TNFa secretion in whole blood stimulation assays with flagellin, LPS or heat-inactivated Salmonella dublin in healthy GSDs
and those with IBD carrying the risk-protective TLR5 haplotype. Whole blood was diluted with twice the volume of RPMI and stimulated
with flagellin, LPS or heat-inactivated Salmonella dublin at different concentrations for 24 hours before production of TNFa was analysed by an ELISA.
The results displayed are the mean values obtained from five dogs, with error bars illustrating standard error of the mean. There was no significant
difference in TNFa response to flagellin, LPS or Salmonella dublin between healthy GSDs and those with IBD all carrying the risk-protective TLR5
haplotype at any of the concentrations tested (p.0.05).
doi:10.1371/journal.pone.0030117.g005
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Cloning of the risk-protective and risk-associated TLR5
haplotype
Primers were designed to incorporate a 59EcoR1- and a 39
HinD3 restriction site, a 59 KOSAK sequence as well as the
removal of the internal stop-codon for both, the risk-protective and
risk-associated sequence (Table 3). The PCR reactions were
carried out with genomic DNA from a healthy GSD carrying the
risk-protective TLR5 haplotype (GTT) and from a GSD with IBD
carrying the risk-associated TLR5 haplotype (ACC) using the Easy
A2 6 master mix (Stratagene, California, USA) by heating to
95uC for 10 min, followed by 35 cycles of 95uC for 1 min, 62uC
for 1 min and 72uC for 3 min and a final extension at 72uC for
7 min. Resulting PCR products were analysed on a 1% agarose/
safeview nucleic acid stain gel (NBS Biologicals, Huntingdon, UK)
using 66 orange loading dye (Fermentas) in 16 Tris-Borate
EDTA (TBE) buffer. Bands of the correct size were excised and
DNA extracted using the Qiagen mini-elute extraction kit,
according to manufacturer’s instructions. Purified cDNA was
subsequently ligated into pSC-A-amp/kan (Agilent Technologies,
UK) and used to transform SoloPack competent cells (Agilent
Technologies, UK) according to the manufacturer’s instructions.
Subsequently, colonies were picked, grown overnight in LB liquid
Ampicillin (50 mgm l
21) broth (Fermentas) and plasmid was
extracted using GenElute plasmid Miniprep Kit (Sigma) according
to the manufacturer’s instructions before sequencing (Geneservice,
Cambridge). To monitor expression in HEK293 cells, the TLR5
constructs were subsequently subcloned by restriction-enzyme
digest into pcDNA3.1-YFP. One Shot TOP10 competent cells
(Invitrogen) were transformed according to the manufacturer’s
instructions and plasmid extracted from cells using the method
described above. The resulting plasmid (caTLR5-YFP) was
sequenced for correct reading frames (Geneservice, Cambridge).
Expression of canine TLR5-YFP in HEK293 cells
HEK293 cells (Invivogen, UK) were cultured at 37uC, 5% CO2
in Dulbecco’s Modified Eagle’s Medium (DMEM, Gibco, UK)
with 10% foetal calf serum (FCS, c-irradiated and filtered at
0.22 mM, Sigma-Aldrich,UK) and Penicillin-Streptomycin (100
units ml
21 and 0.1 mg ml
21 respectively) for untransfected cells.
After transfection with either canine risk-protective or risk-
associated TLR5-YFP using Lipofectamine 2000, stable lines were
created by subsequent selection in geneticin (1000 mgm l
21). After
passaging, transfected and un-transfected HEK293 cells were
analysed for YFP-expression using a FACSAria (BD Biosciences,
Oxford, UK). Human TLR5 transfected HEK cells (Invivogen)
were used as positive control and as a comparison to the canine
system in experiments. To increase homogeneity of expression,
caTLR5-YFP expressing HEK293 cells were sorted on high
expressing cells using the FACSAria, and subsequently analysed by
confocal microscopy. To do so, cells were seeded on to the glass
circle of 35 mm poly-d-lysine coated Glass Bottom Culture Dishes
(MatTek). Dishes were incubated at 37uC and 5% CO2 for
4 hours for the cells to adhere after which 2 ml of DMEM was
added to dishes which were then incubated at 37uC and 5% CO2
for 24 hours. After incubation media was removed and cells were
fixed subsequently by adding 200 ml of 4% paraformaldehyde and
incubating at room temperature for 15 mins. Cells were then
carefully washed twice with sterile PBS. Four micrograms per ml
of Hoechst stain in PBS with 0.05% saponin (Sigma-Aldrich) was
added to cells (100 ml per plate) and left to incubate for 10 mins at
room temperature. Cells were then washed twice with molecular
biology water (Sigma) and 1 drop of vectorshield (Vector
Laboratories) was added to the glass area of each dish. A cover
slip was applied and Eukitt was used to seal the cover slip to the
dish. Dishes were stored at 4uC and away from light until being
analysed using a Leica SP5 RS Confocal Microscope and LSM
510 Browser software.
NF-kB-luciferase Transient Transfection
To assess the effect of caTLR5 SNPs on the ability of the
receptor to confer an intracellular signal, Luciferase (luc)-tagged
NF-kB was transfected into the transfected HEK293 cells, along
with HSV-thymidine kinase promoter (pRL-TK) renilla as a
transfection control. Human TLR5 transfected HEK293, risk-
protective and risk-associated caTLR5 HEK293 cells were plated
into a 24-well plate at 5610
5 cells in 1000 ml serum- and
antibiotic-free DMEM per well and incubated at 37uC5 %C O 2
for 24 hours. Thereafter, 0.5 ml Lipofectamine (Invitrogen, UK)
was added to 12 ml DMEM to make a final volume of 12.5 ml,
Figure 6. Stimulation of TNF-a secretion in whole blood
stimulation assays with flagellin in GSDs with IBD carrying
either the risk-protective TLR5 haplotype (RP) or risk-associ-
ated polymorphisms in TLR5 (RA). Whole blood was diluted with
twice the volume of RPMI and stimulated with 1 ug/ml flagellin (FliC)
for 24 hours before production of TNF-a was analyzed by an ELISA. All
assays were performed in duplicates. The boxes displayed represent
ranges with lines representing the median values obtained from 23
GSDs with IBD carrying the RP TLR5 haplotype and from 5 GSDs with
IBD carrying the risk-associated haplotype in their TLR5 gene (3
different haplotypes: AGAGCT, GGGGTT and GGAGCT).
doi:10.1371/journal.pone.0030117.g006
Table 3. Primer sequence used for PCR amplification of full-length canine TLR5 to incorporate EcoR1 restriction site and KOZAK
sequence to 59 end and to remove stop codon and add HIND3 restriction site to 39 end.
TLR5 restriction site primer FORWARD sequence 59-AAGCTTACCATGGGCCGTCAGCTGG-39
TLR5 restriction site primer REVERSE sequence 59-AGCCAGCTTGGCGACGGCC-39
doi:10.1371/journal.pone.0030117.t003
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kB-luc plasmid and 4 ng pRL-TK renilla plasmid were mixed
together in a final volume of 12.5 ml DMEM and added to the
Lipofectamine/DMEM solution, which was then incubated at RT
for 20 mins. The solution was then topped up with 75 ml DMEM
and the resulting 100 ml solution added to the well. The cells were
incubated at 37uC, 5% CO2, and 400 ml of the desired ligands
(0.1 mg/ml recombinant FliC, 0.01 mg/ml recombinant FliC,
1 mg/ml LPS (Invivogen) or 1 mg/ml PAM3CSK4 (all Invivogen))
were added to the plate 24 hours later. After 24 hours stimulation,
NF-kB-luc and pRL-TK renilla levels were analysed on a
MicroLumat Plus LB96V machine (Berthold Technologies) using
the Dual-Luciferase Reporter Assay System (Promega, UK),
according to the manufacturer’s protocol. Mean luciferase
values were recorded and tabulated using WinGlow software
(v.1.25.00003, Bethold Technologies). All assays were performed
in triplicate.
CXCL8 ELISA
To analyse whether the identified SNPs in caTLR5 do not only
have a potential effect on transcription factor activity, but also on
chemokine production, the R&D Systems Quantikine Human IL-
8 Immunoassay was used to test the supernatant for CXCL8 of
stimulated HEK cells according to the manufacturer’s instructions.
Optical density (OD) was measured at 450 nm with a 610 nm
wavelength correction using a Bio-Tek EL8088 Channel Absor-
bance Reader (Fischer Scientific) within 30 minutes and the data
was analysed using Gen5 Data Analysis Software (Biotek, Fisher
Scientific). All assays were performed in triplicates.
Whole Blood Stimulation Assay for TNFa
In a last set of experiments, we assessed whether similar effects
as seen in the in-vitro assays could be seen in an ex-vivo approach.
To do so, a whole blood stimulation assay was developed. Six
millilitres of venous blood was collected from GSD carrying risk-
associated and risk-protective TLR5 polymorphisms. All dogs had
been referred to the RVC, either for assessment of various illnesses
or for the purpose of a health screen (see table 2). Two millilitres of
blood was submitted for haematology and biochemistry profile.
The residual blood was mixed with RPMI (Gibco) containing
penicillin-streptomycin (200 units/ml and 0.2 mg/ml respectively)
in a 1:2 ratio and 1 ml plated in a 24 well plate. 111.1 mlo f
respective ligand was added to each well (1 mg/ml rFliC and PBS
control) and incubated at 37uCa t5 %C O 2 for 24 hours. The plate
was then spun at 20006g for 4 min and the supernatant harvested
and stored at 280uC until analysed. The Quantikine Canine
TNFa Immunoassay (R&D Systems) was used to measure TNFa
production in the supernatants according to manufacturer’s
instruction. The OD was measured at 450 nm with a 610 nm
wavelength correction using a Bio-Tek EL8088 Channel Absor-
bance Reader within 30 minutes and the data were analysed using
Gen5 Data Analysis Software. All assays were performed in
duplicate.
Statistical analysis
For the NF-kB stimulation assays, data from four independent
experiments consisting of three repeats each were pooled and
presented either as relative luciferase units (RLU) or converted
into fold-increase by comparing with RLU values obtained for
unstimulated cells with media [37]. Pooled results were analysed
using the student’s t-test to determine significant differences
between means of RLU between the risk-protective and risk-
associated TLR5 haplotype cells for the different ligands and
concentrations used in the NF-kB stimulation assays. A Mann-
Whitney U test was used to determine significant differences
between medians of CXCL8 concentrations between the risk-
protective and risk-associated TLR5 cells for the different
concentrations of flagellin used. Similarly, the Mann-Whitney U
test was used to determine significant differences between medians
of TNFa concentrations in GSDs carrying the risk-protective and
risk-associated TLR5 polymorphisms for the different ligands used
in the whole blood stimulation assay. The Mann-Whitney U test
was also used to determine significant differences between medians
of leucocyte subsets (neutrophils, lymphocytes, monocytes and
eosinophils) in GSDs carrying the risk-protective and risk-
associated TLR5 polymorphisms used in the whole blood
stimulation assay. Both, Student’s t-test and Mann-Whitney U
test were carried out using Statistical Package for the Social
Sciences (SPSS) version 15.0 software. Statistical significance was
set at P,0.05. Graphs were constructed using GraphPad Prism 5
software.
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